CPA5 Inhibitors
CPA5 inhibitors represent a class of chemical agents specifically designed to target and hinder the activity of the CPA5 protein, which plays a crucial role in a particular biological process or signaling pathway. These inhibitors are structured to bind to the active site or another critical region of the CPA5 protein, thereby impeding its ability to catalyze reactions or interact with other molecules within the cell. The specificity of CPA5 inhibitors is of paramount importance, as it ensures that the inhibitors exert their effects directly on the CPA5 protein, with minimal off-target interactions that could lead to unwanted complications within the cellular environment. The design of CPA5 inhibitors takes into account the three-dimensional structure of the protein, utilizing the principles of molecular docking and dynamics to achieve a high-affinity interaction that can effectively reduce the functional activity of CPA5. By doing so, these inhibitors can disrupt the protein's role in its specific signaling pathway, leading to a decrease in the downstream effects typically mediated by CPA5's activity.
The development of CPA5 inhibitors is grounded in a thorough understanding of the protein's role within its native pathway. This knowledge enables the rational design of molecules that can modulate the protein's function. Inhibitors might work by preventing substrate binding, altering the protein's conformation to an inactive state, or blocking the association of CPA5 with other proteins or cofactors essential for its activity. The inhibition of CPA5 can affect various cellular processes that are dependent on its function, potentially leading to a cascade of effects within the pathway in which CPA5 is involved. These effects are characterized by a reduction in the biological process that CPA5 would normally promote. The inhibitors are characterized by their ability to sustain this inhibitory action over time, which is crucial for their effectiveness. The precise mechanism of inhibition can vary among different CPA5 inhibitors, with some causing reversible inhibition and others leading to an irreversible loss of CPA5 activity. Each CPA5 inhibitor is unique in its structure and the particular mechanism by which it achieves inhibition, tailored to interact with the protein in a way that ensures the maximum reduction of its activity with the highest specificity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase inhibitor that can impede extracellular matrix degradation, which CPA5 may rely on for proper localization and function. By inhibiting these metalloproteinases, the remodeling of the extracellular matrix is reduced, potentially diminishing CPA5’s ability to contribute to pathological processes. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $275.00 $928.00 $1543.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor that can indirectly inhibit CPA5 by stabilizing the extracellular matrix and preventing the degradation that CPA5 may facilitate, thus disrupting CPA5's functional involvement in proteolysis. | ||||||
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $195.00 $620.00 | 8 | |
Phosphoramidon is a metalloproteinase inhibitor that prevents the breakdown of extracellular matrix components. This indirectly affects CPA5 by maintaining matrix integrity, potentially reducing the accessibility of substrates for CPA5's enzymatic activity. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $110.00 $400.00 $1615.00 | 51 | |
Aprotinin is a serine protease inhibitor that can indirectly affect CPA5 by stabilizing protein substrates within the protease network, which could reduce the cleavage efficiency of CPA5 and thus its functional activity in proteolytic processes. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $72.00 $145.00 $265.00 $489.00 $1399.00 $99.00 | 19 | |
Leupeptin is an inhibitor of serine and cysteine proteases which can indirectly inhibit CPA5 by blocking the activity of proteases within the same cascade as CPA5, potentially reducing CPA5’s involvement and activity in proteolysis. | ||||||
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $50.00 $120.00 $420.00 $834.00 $1836.00 $4896.00 | 33 | |
AEBSF is an irreversible serine protease inhibitor that could indirectly inhibit CPA5 by stabilizing the protease network, potentially decreasing CPA5's ability to process substrates within its activity spectrum. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $119.00 $447.00 | 28 | |
Calpeptin is a calpain inhibitor that, while not directly inhibiting CPA5, could maintain the integrity of substrates that CPA5 acts upon, thus indirectly reducing the functional activity of CPA5 in cellular processes. | ||||||
Chymostatin | 9076-44-2 | sc-202541 sc-202541A sc-202541B sc-202541C sc-202541D | 5 mg 10 mg 25 mg 50 mg 100 mg | $153.00 $255.00 $627.00 $1163.00 $2225.00 | 3 | |
Chymostatin is an inhibitor of chymotrypsin-like proteases and could indirectly inhibit CPA5 by preventing the breakdown of proteins in pathways where CPA5 is active, thereby potentially decreasing CPA5's proteolytic role. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can indirectly affect CPA5 by stabilizing proteins that might be involved in the same pathways or processes as CPA5, therefore potentially reducing CPA5’s functional contribution to these pathways. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that can lead to the accumulation of proteins that CPA5 may otherwise act upon, indirectly affecting CPA5's role in protein turnover and degradation. | ||||||